Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Lowers FY 2013 Earnings Guidance


Friday, 26 Apr 2013 06:30am EDT 

ImmunoGen Inc announced that it now expects net loss for to be between $76 million to $80 million, its net cash used in operations to be between $65 million to $69 million for fiscal 2013. This compares with previous guidance, issued in January 2013, of a projected net loss between $70 million to $74 million, net cash used in operations of between $78 million to $82 million. 

Company Quote

11.52
0.03 +0.26%
22 Aug 2014